MesotheliomaCenter's

Mesothelioma-Line

Curated Journal Articles on Mesothelioma

Evaluating the effect of immune cells on the outcome of patients with mesothelioma

British Journal of Cancer 2017 August 17 [Epub ahead of print] [Link]

Chee SJ, Lopez M, Mellows T3, Gankande S, Moutasim KA, Harris S, Clarke J, Vijayanand P, Thomas GJ1, Ottensmeier CH

Abstract

BACKGROUND:
We systematically assessed the prognostic and predictive value of infiltrating adaptive and innate immune cells in a large cohort of patients with advanced mesothelioma.
METHODS:
A tissue microarray from 302 samples was constructed. Markers of adaptive immune response in T-cells (CD8+, FOXP3+, CD4+, CD45RO+, CD3+) and B-cells (CD20+), and of innate immune response; neutrophils (NP57+), natural killer cells (CD56+) and macrophages (CD68+) were evaluated.
RESULTS:
We found that in the epithelioid tumours, high CD4+ and CD20+ counts, and low FOXP3+, CD68+ and NP57+ counts linked to better outcome. In the non-epithelioid group low CD8+ and low FOXP3+ counts were beneficial.On multivariate analysis low FOXP3+ remained independently associated with survival in both groups. In the epithelioid group additionally high CD4+, high CD20+, and low NP57+ counts were prognostic.
CONCLUSIONS:
Our data demonstrate for the first time, in predominately advanced disease, the association of key markers of adaptive and innate immunity with survival and the differential effect of histology. A better understanding of the immunological drivers of the different subtypes of mesothelioma will assist prognostication and disease-specific clinical decision-making.British Journal of Cancer advance online publication: 17 August 2017; doi:10.1038/bjc.2017.269 www.bjcancer.com.

Both comments and trackbacks are currently closed.